Abstract
| Original language | English |
|---|---|
| Journal | Progress in Retinal and Eye Research |
| Volume | 57 |
| Pages (from-to) | 134-185 |
| Number of pages | 52 |
| ISSN | 1350-9462 |
| DOIs | |
| Publication status | Published - Mar 2017 |
| MoE publication type | A2 Review article in a scientific journal |
Fields of Science
- 317 Pharmacy
- 3125 Otorhinolaryngology, ophthalmology
- Retina
- Vitreous
- Choroid
- Topical
- Intravitreal
- Sub-conjunctival
- Suprachoroidal
- Clearance
- Distribution
- Pharmacokinetic modeling
- Transport
- ENDOTHELIAL GROWTH-FACTOR
- PIGMENT EPITHELIAL-CELLS
- DIABETIC MACULAR EDEMA
- SINGLE INTRAVITREAL INJECTION
- BLOOD-AQUEOUS BARRIER
- NEONATAL FC-RECEPTOR
- HUMAN VITREOUS-HUMOR
- COMPLEMENT REGULATORY PROTEINS
- SERUM-ALBUMIN NANOPARTICLE S
- LEBERS CONGENITAL AMAUROSIS
Cite this
}
Pharmacokinetic aspects of retinal drug delivery. / del Amo, Eva M.; Rimpelä, Anna-Kaisa Irmeli; Heikkinen, Emma ; Kari, Otto K.; Ramsay, Eva; Lajunen, Tatu; Schmitt, Mechthild; Pelkonen, Laura; Bhattacharya, Madhushree; Richardson, Dominique; Subrizi, Astrid ; Turunen, Tiina; Reinisalo, Mika; Itkonen, Jaakko ; Toropainen, Elisa; Casteleijn, Marco G. ; Kidron, Heidi ; Antopolsky, Maxim; Vellonen, Kati-Sisko; Ruponen, Marika; Urtti, Arto .
In: Progress in Retinal and Eye Research, Vol. 57, 03.2017, p. 134-185.Research output: Contribution to journal › Review Article › Scientific › peer-review
TY - JOUR
T1 - Pharmacokinetic aspects of retinal drug delivery
AU - del Amo, Eva M.
AU - Rimpelä, Anna-Kaisa Irmeli
AU - Heikkinen, Emma
AU - Kari, Otto K.
AU - Ramsay, Eva
AU - Lajunen, Tatu
AU - Schmitt, Mechthild
AU - Pelkonen, Laura
AU - Bhattacharya, Madhushree
AU - Richardson, Dominique
AU - Subrizi, Astrid
AU - Turunen, Tiina
AU - Reinisalo, Mika
AU - Itkonen, Jaakko
AU - Toropainen, Elisa
AU - Casteleijn, Marco G.
AU - Kidron, Heidi
AU - Antopolsky, Maxim
AU - Vellonen, Kati-Sisko
AU - Ruponen, Marika
AU - Urtti, Arto
PY - 2017/3
Y1 - 2017/3
N2 - Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.
AB - Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.
KW - 317 Pharmacy
KW - 3125 Otorhinolaryngology, ophthalmology
KW - Retina
KW - Vitreous
KW - Choroid
KW - Topical
KW - Intravitreal
KW - Sub-conjunctival
KW - Suprachoroidal
KW - Clearance
KW - Distribution
KW - Pharmacokinetic modeling
KW - Transport
KW - ENDOTHELIAL GROWTH-FACTOR
KW - PIGMENT EPITHELIAL-CELLS
KW - DIABETIC MACULAR EDEMA
KW - SINGLE INTRAVITREAL INJECTION
KW - BLOOD-AQUEOUS BARRIER
KW - NEONATAL FC-RECEPTOR
KW - HUMAN VITREOUS-HUMOR
KW - COMPLEMENT REGULATORY PROTEINS
KW - SERUM-ALBUMIN NANOPARTICLE S
KW - LEBERS CONGENITAL AMAUROSIS
U2 - 10.1016/j.preteyeres.2016.12.001
DO - 10.1016/j.preteyeres.2016.12.001
M3 - Review Article
VL - 57
SP - 134
EP - 185
JO - Progress in Retinal and Eye Research
JF - Progress in Retinal and Eye Research
SN - 1350-9462
ER -